Sadelain, M., Rivière, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423–431 (2017).
Chang, Z.L. & Chen, Y.Y. CARs: synthetic immunoreceptors for cancer therapy and Beyond. Trends Mol. Med. 23, 430–450 (2017).
Brown, C.E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561–2569 (2016).
Ali, A. et al. HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. J. Virol. 90, 6999–7006 (2016).
Ellebrecht, C.T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179–184 (2016).
Hombach, A. et al. An anti-CD30 chimeric receptor that mediates CD3-ζ-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res. 58, 1116–1119 (1998).
Lanitis, E. et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol. Ther. 20, 633–643 (2012).
Nolan, K.F. et al. Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin. Cancer Res. 5, 3928–3941 (1999).
Westwood, J.A. et al. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J. Immunother. 32, 292–301 (2009).
Ma, Q., DeMarte, L., Wang, Y., Stanners, C.P. & Junghans, R.P. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins. Cancer Gene Ther. 11, 297–306 (2004).
Carpenter, R.O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048–2060 (2013).
McGuinness, R.P. et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum. Gene Ther. 10, 165–173 (1999).
Chmielewski, M. et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 143, 1095–1107. e2 (2012).
Irving, B.A. & Weiss, A. The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891–901 (1991).
Letourneur, F. & Klausner, R.D. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc. Natl. Acad. Sci. USA 88, 8905–8909 (1991).
Romeo, C. & Seed, B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64, 1037–1046 (1991).
Leibly, D.J. et al. A suite of engineered GFP molecules for oligomeric scaffolding. Structure 23, 1754–1768 (2015).
Kirchhofer, A. et al. Modulation of protein properties in living cells using nanobodies. Nat. Struct. Mol. Biol. 17, 133–138 (2010).
Tang, J.C.Y. et al. A nanobody-based system using fluorescent proteins as scaffolds for cell-specific gene manipulation. Cell 154, 928–939 (2013).
Mack, M., Riethmüller, G. & Kufer, P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. USA 92, 7021–7025 (1995).
Urbanska, K. et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 72, 1844–1852 (2012).
Tamada, K. et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin. Cancer Res. 18, 6436–6445 (2012).
Rabinovich, G.A., Gabrilovich, D. & Sotomayor, E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267–296 (2007).
Flavell, R.A., Sanjabi, S., Wrzesinski, S.H. & Licona-Limón, P. The polarization of immune cells in the tumour environment by TGF-β. Nat. Rev. Immunol. 10, 554–567 (2010).
Koehler, H., Kofler, D., Hombach, A. & Abken, H. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. Cancer Res. 67, 2265–2273 (2007).
Bunnell, S.C. et al. T cell receptor ligation induces the formation of dynamically regulated signaling assemblies. J. Cell Biol. 158, 1263–1275 (2002).
Campi, G., Varma, R. & Dustin, M.L. Actin and agonist MHC-peptide complex-dependent T cell receptor microclusters as scaffolds for signaling. J. Exp. Med. 202, 1031–1036 (2005).
Kim, S.T. et al. The alphabeta T cell receptor is an anisotropic mechanosensor. J. Biol. Chem. 284, 31028–31037 (2009).
Li, Y.-C. et al. Cutting edge: mechanical forces acting on T cells immobilized via the TCR complex can trigger TCR signaling. J. Immunol. 184, 5959–5963 (2010).
Liu, B., Chen, W., Evavold, B.D. & Zhu, C. Accumulation of dynamic catch bonds between TCR and agonist peptide-MHC triggers T cell signaling. Cell 157, 357–368 (2014).
Zhang, Y. et al. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res. 70, 1082–1089 (2010).
Hargreaves, P.G. & Al-Shamkhani, A. Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur. J. Immunol. 32, 163–173 (2002).
Schwesinger, F. et al. Unbinding forces of single antibody-antigen complexes correlate with their thermal dissociation rates. Proc. Natl. Acad. Sci. USA 97, 9972–9977 (2000).
Hu, K.H. & Butte, M.J. T cell activation requires force generation. J. Cell Biol. 213, 535–542 (2016).
Zhang, H., Cordoba, S.-P., Dushek, O. & van der Merwe, P.A. Basic residues in the T-cell receptor ζ cytoplasmic domain mediate membrane association and modulate signaling. Proc. Natl. Acad. Sci. USA 108, 19323–19328 (2011).
Dobbins, J. et al. Binding of the cytoplasmic domain of CD28 to the plasma membrane inhibits Lck recruitment and signaling. Sci. Signal. 9, ra75 (2016).
van der Merwe, P.A. & Dushek, O. Mechanisms for T cell receptor triggering. Nat. Rev. Immunol. 11, 47–55 (2011).
Yokosuka, T. et al. Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C θ translocation. Immunity 29, 589–601 (2008).
Sadelain, M. Chimeric antigen receptors: driving immunology towards synthetic biology. Curr. Opin. Immunol. 41, 68–76 (2016).
Kalos, M. & June, C.H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39, 49–60 (2013).
Matsuda, M., Koga, M., Nishida, E. & Ebisuya, M. Synthetic signal propagation through direct cell-cell interaction. Sci. Signal. 5, ra31 (2012).
Gordon, W.R. et al. Mechanical allostery: evidence for a force requirement in the proteolytic activation of Notch. Dev. Cell 33, 729–736 (2015).
Morsut, L. et al. Engineering customized cell sensing and response behaviors using synthetic Notch receptors. Cell 164, 780–791 (2016).
Schwarz, K.A., Daringer, N.M., Dolberg, T.B. & Leonard, J.N. Rewiring human cellular input-output using modular extracellular sensors. Nat. Chem. Biol. 13, 202–209 (2017).
Hanash, S.M., Pitteri, S.J. & Faca, V.M. Mining the plasma proteome for cancer biomarkers. Nature 452, 571–579 (2008).
Hu, S., Loo, J.A. & Wong, D.T. Human body fluid proteome analysis. Proteomics 6, 6326–6353 (2006).
Fedorov, V.D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5, 215ra172 (2013).
Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71–75 (2013).
Grada, Z. et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic Acids 2, e105 (2013).
Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M.C. & Chen, Y.Y. T Cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol. Res. 4, 498–508 (2016).
Jonnalagadda, M. et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol. Ther. 23, 757–768 (2015).
Nguyen, P., Moisini, I. & Geiger, T.L. Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function. Blood 102, 4320–4325 (2003).
Moeller, M. et al. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther. 11, 371–379 (2004).
Zhao, Y. et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563–5574 (2009).
Gressner, A.M., Weiskirchen, R., Breitkopf, K. & Dooley, S. Roles of TGF-beta in hepatic fibrosis. Front. Biosci. 7, d793–d807 (2002).
Junker, U. et al. Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine 8, 794–798 (1996).
Yu, Q. & Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14, 163–176 (2000).
Zhang, Q. et al. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 65, 1761–1769 (2005).
Foster, A.E. et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J. Immunother. 31, 500–505 (2008).
El Hentati, F.-Z., Gruy, F., Iobagiu, C. & Lambert, C. Variability of CD3 membrane expression and T cell activation capacity. Cytometry B Clin. Cytom. 78, 105–114 (2010).